Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022542 · ClinicalTrials.gov registry record · Phase 2
BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00022542: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00022542 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00022542, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of BMS-247550 in treating patients who have advanced soft tissue sarcoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Interventions
- DRUG ixabepilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2001-06 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00022542
The ClinicalTrials.gov registry entry for NCT00022542 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ixabepilone is the first listed.
NCT00022542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00022542 about?
NCT00022542 is a clinical study titled "BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma". Phase II trial to study the effectiveness of BMS-247550 in treating patients who have advanced soft tissue sarcoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
What is the current status of trial NCT00022542?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2001-06. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00022542?
The interventions under investigation include: ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00022542?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.